Regional and cellular gene expression changes in human Huntington's disease brain

Human Molecular Genetics

Volumn 15, Issue 6, 2006, Pages 965-977

  Hodges, Angela ^a,k   Strand, Andrew D ^b   Aragaki, Aaron K ^b   Kuhn, Alexandre ^c   Sengstag, Thierry ^d   Hughes, Gareth ^a   Elliston, Lyn A ^a   Hartog, Cathy ^a   Goldstein, Darlene R ^c   Thu, Doris ^e   Hollingsworth, Zane R ^f   Collin, Francois ^g   Synek, Beth ^h   Holmans, Peter A ^a   Young, Anne B ^f   Wexler, Nancy S ^i,j   Delorenzi, Mauro ^d   Kooperberg, Charles ^b   Augood, Sarah J ^f   Faull, Richard L M ^e   Olson, James M ^b   Jones, Lesley ^a   Luthi Carter, Ruth ^c   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b USA   (United States)

^c EPFL   (Switzerland)

^d National Center of Competence in Research in Molecular Oncology   (Switzerland)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ Columbia University ^*  (United States)

^j Hereditary Disease Foundation   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CAUDATE NUCLEUS; CELL LOSS; CEREBELLUM; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; LASER CAPTURE MICRODISSECTION; MALE; MICROARRAY ANALYSIS; MOTOR CORTEX; NERVE CELL; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; TISSUE HOMOGENATE;

ADULT; AGED; AXONS; BRAIN; CELL DEATH; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 33644783812     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl013     Document Type: Article

References (47)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
2. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P., Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
3. Gutekunst, C.A., Norflus, F. and Hersch, S.M. (2002) The neuropathology of Huntington's disease. In Bates, G.P., Harper, P.S. and Jones, A.L. (eds), Huntington's Disease, 4th edn. OUP, Oxford, UK, pp. 251-275.
4. Tomita, H., Vawter, M.P., Walsh, D.M., Evans, S.J., Choudary, P.V., Li, J., Overman, K.M., Atz, M.E., Myers, R.M. and Jones, E.G. (2004) Effect of agonal and postmortem factors on gene expression profile: Quality control in microarray analyses of postmortem human brain. Biol. Psychiatry, 55, 346-352.
5. Gentleman, R., Carey, V., Bates, D., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J. et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol., 5, R80.
6. Zucker, B., Luthi-Carter, R., Kama, J.A., Dunah, A.W., Stern, E.A., Fox, J.H., Standaert, D.G., Young, A.B. and Augood, S.J. (2005) Transcriptional dysregulation in striatal projection and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet., 14, 179-189.
7. The Gene Ontology Consortium. (2001) Creating the gene ontology resource: Design and implementation. Genome Res., 11, 1425-1433.
8. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
9. Bates, G., Harper, P.S. and Jones, L. (2002) Huntington's Disease, 3rd edn. OUP, Oxford, UK.
10. Luthi-Carter, R., Strand, A.D., Hanson, S.A., Kooperberg, C., Schilling, G., La Spada, A.R., Merry, D.E., Young, A.B., Ross, C.A., Borchelt, D.R. et al. (2002) Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet., 11, 1927-1937.
11. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D. et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum. Mol. Genet., 11, 1911-1926.
12. Edwardson, J.M., Wang, C.-T., Gong, B., Wyttenbach, A., Bai, J., Jackson, M.B., Chapman, E.R. and Morton, A.J. (2003) Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem., 278, 30849-30853.
13. Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G., Scaravilli, F., Easton, D.F., Duden, R., O'Kane, C.J. et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet., 36, 585-595.
14. Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N. and DiFiglia, M. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci., 20, 7268-7278.
15. Curtis, M.A., Penney, E.B., Pearson, J., Dragunow, M., Connor, B. and Faull, R.L.M. (2005) The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain. Neuroscience, 132, 777-788.
16. Wyttenbach, A., Carmichael, J., Swartz, J., Furlong, R.A., Narain, Y., Rankin, J. and Rubinsztein, D.C. (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA, 97, 2898-2903.
17. Jana, N.R., Tanaka, M., Wang, G. and Nukina, N. (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 9, 2009-2018.
18. Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L. and Bonini, N.M. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 23, 425-428.
19. Kiehl, T.R., Olson, J.M. and Pulst, S.M. (2001) The Hereditary Disease Array Group (HDAG) - microarrays, models and mechanisms: A collaboration update. Curr. Genomics, 2, 221-229.
20. Chan, E.Y.W., Luthi-Carter, R., Strand, A., Solano, S.M., Hanson, S.A., DeJohn, M.M., Kooperberg, C., Chase, K.O., DiFiglia, M., Young, A.B. et al. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet., 11, 1939-1951.
21. Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J.M. and Cattaneo, E. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet., 11, 1953-1965.
22. Orr, H.T. (2002) Microarrays and polyglutamine disorders: Reports from the Hereditary Disease Array Group. Hum. Mol. Genet., 11, 1909-1910.
23. Lieberman, A.P., Harmison, G., Strand, A.D., Olson, J.M. and Fischbeck, K.H. (2002) Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet., 11, 1967-1976.
24. Xu, X.L., Olson, J.M. and Zhao, L.P. (2002) A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Hum. Mol. Genet., 11, 1977-1985.
25. Rosas, H.D., Koroshetz, W.J., Chen, Y.I., Skeuse, C., Vangel, M., Cudkowicz, M.E., Caplan, K., Marek, K., Seidman, L.J., Makris, N. et al. (2003) Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology, 60, 1615-1620.
26. Richfield, E.K., Maguire-Zeiss, K.A., Cox, C., Gilmore, J. and Voorn, P. (1995) Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol., 37, 335-343.
27. Augood, S.J., Faull, R.L.M., Love, D.R. and Emson, P.C. (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellular in situ hybridization study. Neuroscience, 72, 1023-1036.
28. Augood, S.J., Faull, R.L.M. and Emson, P.C. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 42, 215-221.
29. Arzberger, T., Krampfl, K., Leimgruber, S. and Weindl, A. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J. Neuropathol. Exp. Neurol., 56, 440-454.
30. Glass, M., Dragunow, M. and Faull, R.L.M. (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97, 505-519.
31. Reisine, T.D., Fields, J.Z., Stern, L.Z., Johnson, P.C., Bird, E.D. and Yamamura, H.I. (1977) Alterations in dopaminergic receptors in Huntington's disease. Life Sci., 21, 1123-1128.
32. Richfield, E.K., O'Brien, C.F., Eskin, T. and Shoulson, I. (1991) Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett., 132, 121-126.
33. Seto-Ohshima, A., Emson, P.C., Lawson, E., Mountjoy, C.Q. and Carrasco, L.H. (1988) Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet, 1, 1252-1255.
34. Mizuno, H., Shibayama, H., Tanaka, F., Doyu, M., Sobue, G., Iwata, H., Kobayashi, H., Yamada, K., Iwai, K., Takeuchi, T. et al. (2000) An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings. Clin. Neuropathol., 19, 94-103.
35. Caramins, M., Halliday, G., McCusker, E. and Trent, R.J. (2003) Genetically confirmed clinical Huntington's disease with no observable cell loss. J. Neurol. Neurosurg. Psychiatry, 74, 968-970.
36. Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P. and Davies, S.W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 97, 8093-8097.
37. Stack, E.C., Kubilus, J.K., Smith, K., Cormier, K., Del Signore, S.J., Guelin, E., Ryu, H., Hersch, S. and Ferrante, R.J. (2005) Chronology of behavioral symptoms and neuropathologic sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol., 490, 354-370.
38. Zhai, Z., Jeong, H., Cui, L., Krainc, D. and Tjian, R. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell, 123, 1241-1253.
39. Tobin, A.J. and Signer, E.R. (2000) Huntington's disease: The challenge for cell biologists. Trends Cell Biol., 10, 531-536.
40. Warner, J.P., Barron, L.H. and Brock, D.J. (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol. Cell. Probes, 7, 235-239.
41. Li, C., and Wong, W.H. (2001) Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc. Natl Acad. Sci. USA, 98, 31-36.
42. Collin, F. (2004) Analysis of oligonucleotide data with a view to quality assessment. Department of Statistics. University of California, Berkeley.
43. Mootha, V.K., Lindgren, C.M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E. et al. (2003) PGC-1[alpha]-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet., 34, 267-273.
44. Bolstad, B.M., Irizarry R.A., Astrand, M. and Speed, T.P. (2003) A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics, 19, 185-193.
45. Irizarry, R.A., Bolstad, B.M., Collin, F., Cope, L.M., Hobbs, B. and Speed, T.P. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res., 31, e15.
46. Gautier, L., Cope, L., Bolstad, B.M., and Irizarry, R.A. (2004) affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 203, 307-315.
47. Smyth, G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 2004, 3, Article 3.